CER Daily Newsfeed

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point.

(1/10, David Wainer and Jon Sindreu, The Wall Street Journal) comments “...In Europe, pharmaceutical companies face strict price regulations and cost-effectiveness assessments, whereas the U.S. approval process focuses solely on whether a drug is safe and effective, allowing drug companies to more freely set the price of their medicines. Many drugs launched at high prices in the U.S. are unavailable in Europe, where their cost is carefully tied to their perceived benefit. But it is hard to argue with the idea that, by paying more, Americans seed the rest of the world with innovation.” Subscription Required

Patrizia Cavazzoni, Key FDA Official, to Leave Agency

(1/10, Ned Pagliarulo, Biopharma Dive) reports “...Cavazzoni joined the FDA’s Center for Drug Evaluation and Research seven years ago and in 2021 was picked to serve at its head, replacing longtime leader Janet Woodcock...Cavazzoni joined the FDA’s Center for Drug Evaluation and Research seven years ago and in 2021 was picked to serve at its head, replacing longtime leader Janet Woodcock.” Full